학술논문
Dostarlimab (Dos) or pembrolizumab (Pem) plus chemotherapy (CT) in previously untreated metastatic non-squamous non-small cell lung cancer (NSCLC): Patient (Pt) and disease characteristics subgroup analyses from the PERLA trial
Document Type
Journal
Author
Source
Subject
Language
English
ISSN
15561380